How to Build a Dental AI ROI Model You Can Defend

You've seen the glossy ROI one-pagers built on best-case assumptions by vendors. Here's how to build the model you can actually defend.

You've already seen the deck. Treatment acceptance lift of 15 to 25 percent, 10x ROI, payback in under a year. The numbers look compelling until your COO asks how adoption was modeled and the answer, when you press, is that it wasn't. Vendor promises about ROI mean nothing if clinicians don't use the tool, and no vendor has handed you a model you can put in front of a board without rebuilding it from scratch.

Why Every Dental AI ROI Model You've Been Handed Is Already Broken

Every input in a vendor-built ROI model is set to make the product look good. Treatment acceptance lift is modeled at the high end of the range. Adoption is assumed at 90 percent or above. Implementation costs are minimized or omitted entirely. The model looks clean until your COO asks how adoption was modeled, and the answer is that it wasn't.

The financial consequence is specific. If adoption lands at 60 percent instead of 90 percent, the revenue assumption doesn't compress by 30 percent. It breaks. The fixed cost of deployment doesn't compress with it. The payback period you approved doubles. The rollout budget you committed is now underwater.

This is also the operational consequence your CEO is carrying: a track record of failed technology rollouts where the investment was approved on vendor projections and the adoption never materialized. Adoption risk is the central variable in this investment, not the cost of the technology itself.

A defensible model requires three things the vendor's model doesn't provide: conservative inputs the CFO controls, adoption modeled as a sensitivity variable across multiple scenarios, and a pilot-first structure that gates rollout capital on measured outcomes rather than projected ones.

What a Finance-First Dental AI ROI Model Actually Looks Like

DSOs that build defensible ROI models don't start with vendor projections. They start with their own practice data, set conservative inputs, and treat adoption as a stress-test variable rather than a footnote. The model has four required input layers.

Treatment acceptance lift is the primary revenue driver. The range is 15 to 25 percent. Model base case at 15 percent, base-expected at 20 percent, and upside at 25 percent. The model is not built on the high end. That is the first structural signal that you own the assumptions, not the vendor.

Provider mix and average production per procedure make the model DSO-specific. A group with a high GP-to-specialist ratio has a different revenue ceiling than one with significant perio or ortho volume. A generic per-location average produces a generic output. Your practice mix matters for the model.

Adoption rate as a sensitivity variable is where vendor models break. Run the ROI calculation at 60 percent, 80 percent, and 95 percent utilization. Identify the adoption floor: the minimum utilization rate at which the investment still produces an acceptable payback period. The model isn't biased if you set the adoption assumption yourself, including the downside scenario.

Full implementation costs, including ramp time, belong inside the model. Training time, integration costs, and a 90-day ramp before full utilization are real costs. A model that excludes them isn't conservative, it's incomplete.

The Proof Behind the Inputs And the Pilot Structure That Validates Them

The pilot-first structure is the mechanism that converts a vendor promise into a CFO-owned projection. Three to five locations prove ROI before rollout capital is committed. You aren't projecting adoption costs at scale. You are measuring them at a controlled sample.

The 15 to 25 percent treatment acceptance lift is not arbitrary. In clinical data, 100 percent of dentists found more caries with Overjet's Vision AI, and 91 percent found more periodontal disease. More findings, presented with AI-assisted visualization, produce higher acceptance. Your conservative 15 percent input is grounded in clinical mechanism, not vendor optimism.

Daily utilization tracking with same-day intervention is not a clinical feature. It is a financial risk-mitigation tool. If adoption drops below the model's assumption, the revenue projection erodes in real time. Daily tracking with same-day intervention gives you a live signal rather than a quarterly surprise, and keeps actual versus projected spend on track.

The 10x average ROI for dental groups is a benchmark output, not a starting assumption. If your conservative model, built at 15 percent lift and 70 percent adoption with full implementation costs included, produces 6 to 8x, the 10x benchmark is credible. A payback period under 12 months at conservative inputs is the threshold that moves this from interesting to approved.

Most models omit claims processing speed entirely. For a DSO with 30 or more locations, a 5x improvement in claims decisions is a working capital story. It shortens the cash conversion cycle independent of production uplift and belongs in the model as a secondary variable, not a footnote.

You now have a model framework built on inputs you set, stress-tested against the adoption scenario most likely to kill the investment. You are no longer dependent on a vendor projection to answer the board's question about per-location dollar impact. You have your own number, with your own assumptions, and a pilot structure that will validate or revise it before rollout capital is committed.

Schedule a call to see how Overjet's pilot-first model for Vision AI maps to this framework and produces the exportable, board-ready output you need to walk into that room. The CFO who owns the model owns the conversation. The CFO who gates rollout on pilot outcomes is the one who doesn't have to defend a failed technology investment twelve months from now.